Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841206 | 1.00 | CA2 (0.47) | CA2CA1CA12CA3CA6 | |
| SCHEMBL3841209 | 1.00 | CA2 (0.47) | CA2CA1CA12CA3CA6 | |
| SCHEMBL9131968 | 0.81 | CA2 (0.45) | CA2CA1CA12CA3CA6 | |
| SCHEMBL9131966 | 0.81 | CA2 (0.45) | CA2CA1CA12CA3CA6 | |
| SCHEMBL11814265 | 0.81 | ALDH1A1 (0.33) | LMNAALDH1A1TSHR | |
| SCHEMBL31204043 | 0.76 | GSK3B (0.49) | GSK3BENPP2ALDH1A1TSHRFBP1 | |
| SCHEMBL9133597 | 0.76 | CYP2A6 (0.44) | CA2CA1CA12CA3CA6 | |
| SCHEMBL4397352 | 0.76 | GSK3B (0.49) | GSK3BENPP2ALDH1A1TSHRFBP1 | |
| SCHEMBL9133593 | 0.76 | CYP2A6 (0.44) | CA2CA1CA12CA3CA6 | |
| SCHEMBL4397349 | 0.76 | GSK3B (0.49) | GSK3BENPP2ALDH1A1TSHRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926308-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2880027-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-2880027-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014019967-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| WO-2009005646-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20060166906-A1 | 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance | ABBOTT LABORATORIES | 2006-07-27 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1328534-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | Abbott Laboratories (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032919-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | ABBOTT LABORATORIES (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166906-A1 | 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance | CYP2D6, CYP2B6, UGT1A6 | CA2 4747/4885CA1 4874/4885CA12 4552/4885 |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | CA2 3771/4885CA1 3472/4885CA12 4237/4885 |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR180, GPR119, CNR1 | CA2 3783/4885CA1 4822/4885CA12 4811/4885 |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | CA2 587/4885CA1 1108/4885CA12 2146/4885 |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR119, FFAR1, FFAR2 | CA2 3946/4885CA1 4865/4885CA12 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.